Alkermes plc (Nasdaq: ALKS) has appointed Joshua Reed as Chief Financial Officer (CFO) effective September 15, 2025.
Mr. Reed brings over 30 years of financial leadership experience with a focus in the biotechnology and pharmaceutical sectors.
His appointment aims to support continued innovation, operational excellence, and long-term growth at Alkermes.
Joshua Reed's Appointment
Effectiveness as CFO from September 15, 2025, to support financial strategy and strategic priorities.
Experience and Expertise
Over 30 years of financial leadership in biotechnology and pharmaceutical sectors, previously CFO at Omega Therapeutics and Aldeyra Therapeutics.
Educational Background
Bachelor of Science in Finance from Rutgers University and MBA from the University of Michigan's Ross School of Business.
- Joshua Reed's appointment signifies a strategic move to strengthen financial leadership at Alkermes, enhancing focus on driving performance and long-term value.
- His extensive experience in the biopharmaceutical industry is expected to bring valuable financial acumen and strategic insight to the company.
Alkermes plc welcomes Joshua Reed as Chief Financial Officer, signaling a commitment to fostering financial excellence and growth. His expertise in the industry is set to contribute significantly to Alkermes' strategic goals.